Methylparaben

Methylparaben

SCHEMBL3929092

COC(=O)c1ccc(O)cc1.NC(N)=O

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.87
CA2 P00918 8/20 0.87
CA12 O43570 5/20 0.87
CA7 P43166 5/20 0.87
CA9 Q16790 5/20 0.87
CA14 Q9ULX7 5/20 0.87
ALDH1A1 P00352 3/20 0.62
LMNA P02545 1/20 0.62
GAA P10253 1/20 0.62
TDP1 Q9NUW8 1/20 0.59
MAPT P10636 2/20 0.59
LOXL2 Q9Y4K0 1/20 0.57
TSHR P16473 1/20 0.56
XDH P47989 1/20 0.53
ESR1 P03372 1/20 0.53
ESR2 Q92731 1/20 0.53
STS P08842 1/20 0.52
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylparaben SCHEMBL321534 0.93 CA1 (1.00) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL4440 0.93 CA1 (1.00) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL475867 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL21274302 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL48757 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL16029235 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL2810862 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL8779118 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL6315862 0.91 CA1 (0.95) CA1CA2CA12CA7CA9
Methylparaben SCHEMBL1699480 0.91 CA1 (0.95) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668993-A1 METHODS OF TREATING LIVER DISEASES Camp4 Therapeutics Corporation (US) 2020-06-24 EP disclosed
WO-2019036430-A1 METHODS OF TREATING LIVER DISEASES CAMP4 THERAPEUTICS CORPORATION (US) 2019-02-21 WO disclosed
CN-107661240-A A kind of Submicron Emulsion repairs stoste composition, its preparation method and includes its cosmetic composition 济南佐康商贸有限公司 2018-02-06 CN disclosed
US-20090318571-A1 Hydrocolloids and Process Therefor LUBRIZOL ADVANCED MATERIALS, INC. (US) 2009-12-24 US disclosed
US-20080139765-A1 Polymers having improved cosmetic wear properties SPIEGEL MICHAEL 2008-06-12 US disclosed
US-20050129643-A1 Dispersing and wet-mincing an algal extract, such as carrageenan or alginates, in water; colorless, odorless and tasteless gelling agents, thickeners for foods, feeds, cosmetics and pharmaceuticals with improved viscosity, gel strength and break strength; shampoo LUBRIZOL ADVANCED MATERIALS, INC. 2005-06-16 US disclosed
US-20050075497-A1 Hydrocolloids and process therefor LUBRIZOL ADVANCED MATERIALS, INC. 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050129643-A1 Dispersing and wet-mincing an algal extract, such as carrageenan or alginates, in water; colorless, odorless and tasteless gelling agents, thickeners for foods, feeds, cosmetics and pharmaceuticals with improved viscosity, gel strength and break strength; shampoo ALG1, PCNA, ALG3 CA1 4231/4885CA2 2248/4885CA12 2128/4885
US-20080139765-A1 Polymers having improved cosmetic wear properties CUTA, TREH, CETP CA1 1561/4885CA2 991/4885CA12 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.